Brain tumor patients with severe symptoms may get a new treatment option

NCT ID NCT03623347

Completed Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, bevacizumab and temozolomide, given before standard chemoradiotherapy in 70 patients with newly diagnosed glioblastoma who had severe neurological symptoms. The goal was to reduce tumor size and improve symptoms enough to allow patients to receive standard treatment. The study looked at how many patients could then undergo optimal chemoradiotherapy and how their survival and quality of life were affected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab and temozolomide
What this could lead to: If this approach works, it could allow more patients with severe glioblastoma to receive life-extending chemoradiotherapy.
What could go wrong: This is a small, early-phase study with only 70 participants. The drugs may not shrink the tumor enough, and side effects like bleeding or high blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMORADIOTHERAPY

Contacts and locations

Locations

CHU Amiens-Picardie

Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.